Weight Gain During Antipsychotic Treatment in Children, Adolescents, and Adults: A Disproportionality Analysis in the Global Pharmacovigilance Database, Vigibase
Journal
Drug safety
ISSN: 1179-1942
Titre abrégé: Drug Saf
Pays: New Zealand
ID NLM: 9002928
Informations de publication
Date de publication:
01 2023
01 2023
Historique:
accepted:
18
10
2022
pubmed:
3
12
2022
medline:
12
1
2023
entrez:
2
12
2022
Statut:
ppublish
Résumé
While antipsychotic-induced weight gain has been widely described in adults, it has yet to be better characterized in children and adolescents. The aim of this study was to assess antipsychotic-induced weight-gain reporting in children and adolescents as compared to adults, and according to the type of antipsychotic. The study is an observational, case-non-case study using individual case safety reports from the WHO global pharmacovigilance database VigiBase Among 282,224 antipsychotic-related spontaneous reports included in this analysis, we identified 16,881 (6.0%) weight-gain cases. Disproportionality in weight-gain reporting was found in children (adjusted ROR (aROR) 3.6; 95% CI 3.3-3.8) and in adolescents (aROR 2.3; 95% CI 2.2-2.4) compared to adults. Use of risperidone was associated with the highest increase in weight-gain reporting in children (aROR 4.9; 95% CI 3.9-6.1) and adolescents (aROR 3.6; 95% CI 3.1-4.1). Compared to adults, weight-gain reporting with antipsychotics was disproportionally higher in the pediatric population, especially in children under 12 years of age. Considering the impact of weight gain on global morbidity and mortality, physicians should closely monitor weight gain in young patients, especially children on risperidone.
Identifiants
pubmed: 36459374
doi: 10.1007/s40264-022-01252-6
pii: 10.1007/s40264-022-01252-6
doi:
Substances chimiques
Antipsychotic Agents
0
Risperidone
L6UH7ZF8HC
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
77-85Informations de copyright
© 2022. The Author(s), under exclusive licence to Springer Nature Switzerland AG.
Références
Fallah MS, Shaikh MR, Neupane B, Rusiecki D, Bennett TA, Beyene J. Atypical antipsychotics for irritability in pediatric autism: a systematic review and network meta-analysis. J Child Adolesc Psychopharmacol. 2019;29(3):168–80.
Kaguelidou F, Holstiege J, Schink T, Bezemer I, Poluzzi E, Mazzaglia G, et al. Use of antipsychotics in children and adolescents: a picture from the ARITMO population-based European cohort study. Epidemiol Psychiatr Sci. 2020;20(29): e117.
Kalverdijk LJ, Bachmann CJ, Aagaard L, Burcu M, Glaeske G, Hoffmann F, et al. A multi-national comparison of antipsychotic drug use in children and adolescents, 2005–2012. Child Adolesc Psychiatry Ment Health. 2017;11:55.
Krause M, Zhu Y, Huhn M, Schneider-Thoma J, Bighelli I, Chaimani A, et al. Efficacy, acceptability, and tolerability of antipsychotics in children and adolescents with schizophrenia: a network meta-analysis. Eur Neuropsychopharmacol. 2018;28(6):659–74.
Vitiello B, Davico C. Twenty years of progress in paediatric psychopharmacology: accomplishments and unmet needs. Evid Based Ment Health. 2018;21(4): e10.
Bai Y, Liu T, Xu A, Yang H, Gao K. Comparison of common side effects from mood stabilizers and antipsychotics between pediatric and adult patients with bipolar disorder: a systematic review of randomized, double-blind, placebo-controlled trials. Expert Opin Drug Saf. 2019;18(8):703–17.
Hong M, Lee SY, Han J, Park JC, Lee YJ, Hwangbo R, et al. Prescription trends of psychotropics in children and adolescents with autism based on nationwide health insurance data. J Korean Med Sci. 2017;32(10):1687–93.
Ching H, Pringsheim T. Aripiprazole for autism spectrum disorders (ASD). Cochrane Database Syst Rev. 2012;16(5):CD009043.
Bak M, Fransen A, Janssen J, van Os J, Drukker M. Almost all antipsychotics result in weight gain: a meta-analysis. PLoS ONE. 2014;9(4): e94112.
Pillinger T, McCutcheon RA, Vano L, Mizuno Y, Arumuham A, Hindley G, et al. Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta-analysis. Lancet Psychiatry. 2020;7(1):64–77.
McIntyre RS, McCann SM, Kennedy SH. Antipsychotic metabolic effects: weight gain, diabetes mellitus, and lipid abnormalities. Can J Psychiatry. 2001;46(3):273–81.
Pringsheim T, Panagiotopoulos C, Davidson J, Ho J, Canadian Alliance for Monitoring E, Safety of Antipsychotics in Children guideline g. Evidence-based recommendations for monitoring safety of second-generation antipsychotics in children and youth. Paediatr Child Health. 2011;16(9):581–9.
Caccia S. Safety and pharmacokinetics of atypical antipsychotics in children and adolescents. Paediatr Drugs. 2013;15(3):217–33.
De Hert M, Dobbelaere M, Sheridan EM, Cohen D, Correll CU. Metabolic and endocrine adverse effects of second-generation antipsychotics in children and adolescents: a systematic review of randomized, placebo controlled trials and guidelines for clinical practice. Eur Psychiatry. 2011;26(3):144–58.
Kryzhanovskaya LA, Xu W, Millen BA, Acharya N, Jen KY, Osuntokun O. Comparison of long-term (at least 24 weeks) weight gain and metabolic changes between adolescents and adults treated with olanzapine. J Child Adolesc Psychopharmacol. 2012;22(2):157–65.
Chung YS, Shao SC, Chi MH, Lin SJ, Su CC, Kao Yang YH, et al. Comparative cardiometabolic risk of antipsychotics in children, adolescents and young adults. Eur Child Adolesc Psychiatry. 2020.
Correll CU, Sheridan EM, DelBello MP. Antipsychotic and mood stabilizer efficacy and tolerability in pediatric and adult patients with bipolar I mania: a comparative analysis of acute, randomized, placebo-controlled trials. Bipolar Disord. 2010;12(2):116–41.
Cicala G, Barbieri MA, Santoro V, Tata C, Colucci PV, Vanadia F, et al. Safety and tolerability of antipsychotic drugs in pediatric patients: data from a 1-year naturalistic study. Front Psychiatry. 2020;11:152.
Leucht S, Cipriani A, Spineli L, Mavridis D, Orey D, Richter F, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet. 2013;382(9896):951–62.
https://www.who-umc.org/vigibase/vigibase/ .
Lindquist M. VigiBase, the WHO Global ICSR database system: basic facts. Ther Innov Regul Sci. 2008;42:409–19.
Chouchana L, Blet A, Al-Khalaf M, Kafil TS, Nair G, Robblee J, et al. features of inflammatory heart reactions following mRNA COVID-19 vaccination at a global level. Clin Pharmacol Ther. 2022;111(3):605–13.
Khouri C, Petit C, Tod M, Lepelley M, Revol B, Roustit M, et al. Adverse drug reaction risks obtained from meta-analyses and pharmacovigilance disproportionality analyses are correlated in most cases. J Clin Epidemiol. 2021;134:14–21.
Bergvall T, Noren GN, Lindquist M. vigiGrade: a tool to identify well-documented individual case reports and highlight systematic data quality issues. Drug Saf. 2014;37(1):65–77.
Edwards IR, Aronson JK. Adverse drug reactions: definitions, diagnosis, and management. Lancet. 2000;356(9237):1255–9.
EMA, 2017, Guideline on good pharmacovigilance practices (GVP). Module IX Addendum I—methodological aspects of signal detection from spontaneous reports of suspected adverse reactions, 22 November 2017.
Solmi M, Fornaro M, Ostinelli EG, Zangani C, Croatto G, Monaco F, et al. Safety of 80 antidepressants, antipsychotics, anti-attention-deficit/hyperactivity medications and mood stabilizers in children and adolescents with psychiatric disorders: a large scale systematic meta-review of 78 adverse effects. World Psychiatry. 2020;19(2):214–32.
Yoon Y, Wink LK, Pedapati EV, Horn PS, Erickson CA. Weight gain effects of second-generation antipsychotic treatment in autism spectrum disorder. J Child Adolesc Psychopharmacol. 2016;26(9):822–7.
Blake KV, Saint-Raymond A, Zaccaria C, Domergue F, Pelle B, Slattery J. Enhanced paediatric pharmacovigilance at the european medicines agency: a novel query applied to adverse drug reaction reports. Paediatr Drugs. 2016;18(1):55–63.
Blake KV, Zaccaria C, Domergue F, La Mache E, Saint-Raymond A, Hidalgo-Simon A. Comparison between paediatric and adult suspected adverse drug reactions reported to the European medicines agency: implications for pharmacovigilance. Paediatr Drugs. 2014;16(4):309–19.
Faillie JL. Case-non-case studies: principle, methods, bias and interpretation. Therapie. 2019;74(2):225–32.
Montastruc JL, Sommet A, Bagheri H, Lapeyre-Mestre M. Benefits and strengths of the disproportionality analysis for identification of adverse drug reactions in a pharmacovigilance database. Br J Clin Pharmacol. 2011;72(6):905–8.
Sabus A, Feinstein J, Romani P, Goldson E, Blackmer A. Management of self-injurious behaviors in children with neurodevelopmental disorders: a pharmacotherapy overview. Pharmacotherapy. 2019;39(6):645–64.
Sandberg L, Taavola H, Aoki Y, Chandler R, Noren GN. Risk factor considerations in statistical signal detection: using subgroup disproportionality to uncover risk groups for adverse drug reactions in VigiBase. Drug Saf. 2020;43(10):999–1009.
Halfdanarson O, Zoega H, Aagaard L, Bernardo M, Brandt L, Fuste AC, et al. International trends in antipsychotic use: a study in 16 countries, 2005–2014. Eur Neuropsychopharmacol. 2017;27(10):1064–76.
Olfson M, King M, Schoenbaum M. Treatment of young people with antipsychotic medications in the United States. JAMA Psychiat. 2015;72(9):867–74.
Dalsgaard S, Thorsteinsson E, Trabjerg BB, Schullehner J, Plana-Ripoll O, Brikell I, et al. Incidence rates and cumulative incidences of the full spectrum of diagnosed mental disorders in childhood and adolescence. JAMA Psychiat. 2020;77(2):155–64.
Chen W, Cepoiu-Martin M, Stang A, Duncan D, Symonds C, Cooke L, et al. Antipsychotic prescribing and safety monitoring practices in children and youth: a population-based study in Alberta, Canada. Clin Drug Investig. 2018;38(5):449–55.
Pozzi M, Bertella S, Cattaneo D, Molteni M, Perrone V, Carnovale C, et al. Are non-serious adverse reactions to psychiatric drugs really non-serious? J Child Adolesc Psychopharmacol. 2013;23(6):394–400.
McClellan J, Stock S, American Academy of C, Adolescent Psychiatry Committee on Quality I. Practice parameter for the assessment and treatment of children and adolescents with schizophrenia. J Am Acad Child Adolesc Psychiatry. 2013;52(9):976–90.
Lee ES, Kronsberg H, Findling RL. Psychopharmacologic treatment of schizophrenia in adolescents and children. Child Adolesc Psychiatr Clin N Am. 2020;29(1):183–210.
Volpato AM, Zugno AI, Quevedo J. Recent evidence and potential mechanisms underlying weight gain and insulin resistance due to atypical antipsychotics. Braz J Psychiatry. 2013;35(3):295–304.
Kearns GL, Abdel-Rahman SM, Alander SW, Blowey DL, Leeder JS, Kauffman RE. Developmental pharmacology–drug disposition, action, and therapy in infants and children. N Engl J Med. 2003;349(12):1157–67.
Ronsley R, Nguyen D, Davidson J, Panagiotopoulos C. Increased risk of obesity and metabolic dysregulation following 12 months of second-generation antipsychotic treatment in children: a prospective cohort study. Can J Psychiatry. 2015;60(10):441–50.
Safer DJ. A comparison of risperidone-induced weight gain across the age span. J Clin Psychopharmacol. 2004;24(4):429–36.
Hirsch L, Yang J, Bresee L, Jette N, Patten S, Pringsheim T. Second-generation antipsychotics and metabolic side effects: a systematic review of population-based studies. Drug Saf. 2017;40(9):771–81.
Chung YS, Shao SC, Chi MH, Lin SJ, Su CC, Kao Yang YH, et al. Comparative cardiometabolic risk of antipsychotics in children, adolescents and young adults. Eur Child Adolesc Psychiatry. 2021;30(5):769–83.
De Hert M, Detraux J, van Winkel R, Yu W, Correll CU. Metabolic and cardiovascular adverse effects associated with antipsychotic drugs. Nat Rev Endocrinol. 2011;8(2):114–26.
Lambert M, Niehaus V, Correll C. Pharmacotherapy in children and adolescents at clinical-high risk for psychosis and bipolar disorder. Pharmacopsychiatry. 2016;49(6):229–44.
Maayan L, Correll CU. Weight gain and metabolic risks associated with antipsychotic medications in children and adolescents. J Child Adolesc Psychopharmacol. 2011;21(6):517–35.
Brixner DI, Said Q, Corey-Lisle PK, Tuomari AV, L’Italien GJ, Stockdale W, et al. Naturalistic impact of second-generation antipsychotics on weight gain. Ann Pharmacother. 2006;40(4):626–32.
Schneider C, Corrigall R, Hayes D, Kyriakopoulos M, Frangou S. Systematic review of the efficacy and tolerability of clozapine in the treatment of youth with early onset schizophrenia. Eur Psychiatry. 2014;29(1):1–10.
Gahr M, Eller J, Cabanis M, Hiemke C, Freudenmann RW, Connemann BJ, et al. Drug safety and adverse drug reaction reporting behavior related to outpatient opioid replacement therapy: Results from a survey among physicians. J Subst Abuse Treat. 2017;74:7–15.
Steurbaut S, Hanssens Y. Pharmacovigilance: empowering healthcare professionals and patients. Int J Clin Pharm. 2014;36(5):859–62.